| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8679274 | Thrombosis Research | 2018 | 5 Pages |
Abstract
The limited available evidence raises concern regarding embryo-foetal safety, with high incidence of miscarriages and a 4% rate of anomalies with the use of rivaroxaban. Not enough data are available to judge safety and efficacy of the use of DOACs during pregnancy.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Heleen Lameijer, Jan J.J. Aalberts, Dirk J. van Veldhuisen, Karina Meijer, Petronella G. Pieper,